Korro Bio Announces Positive Preclinical Results for KRRO-111 in AATD Treatment

Article summary

Korro Bio reported successful preclinical data for its KRRO-111 program, demonstrating significant RNA editing and potential to treat both liver and lung manifestations of alpha-1 antitrypsin deficiency.